6:18 PM
 | 
May 06, 2009
 |  BC Extra  |  Company News

Biovail regains U.S. rights to Wellbutrin XL

Biovail Corp. (TSX:BVF; NYSE:BVF) will reacquire U.S. marketing rights to Wellbutrin XL bupropion extended-release tablets from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for US$510 million. The pharma, which has...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >